Fucoxanthin: A Promising Medicinal and Nutritional Ingredient

Zhang, Hui; Tang, Yu-Wen; Ying, Zhang; Zhang, Shuofeng; Qu, Jing; Wang, Xu; Kong, Ran; Han, Chunchao; Liu, Zhenquan

doi:10.1155/2015/723515

Cited by 163 publications

(107 citation statements)

References 69 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…However, UV filters or boosters should be stable under UV exposure, since their exposure to sunlight might lead to photodegradation reactions that can compromise their physical properties and lead to the formation of undesirable photoproducts [42]. Zhang and Tang [43] discussed that the instability of carotenes is related to the poly chain conjugate and its susceptibility to oxidation, isomerization by heat, light, and chemical interactions. After analyzing the chemical UVA/VIS photoinstability of fucoxanthin, with degradation being over the acceptable range of 20% after a 6 J/cm 2 UVA dose, we added fucoxanthin at 0.5% to a sunscreen formulation to assess photostability at a 27.5 J/cm 2 UVA dose.…”

Section: Discussionmentioning

confidence: 99%

Fucoxanthin for Topical Administration, a Phototoxic vs. Photoprotective Potential in a Tiered Strategy Assessed by In Vitro Methods

et al. 2020

View full text Add to dashboard Cite

Fucoxanthin possesses a well-described antioxidant activity that might be useful for human skin photoprotection. However, there is a lack of scientific information regarding its properties when applied onto human skin. Thus, the objective of the present study was to assess the photoprotective and phototoxicity potential of fucoxanthin based on its ultraviolet (UVB 280–320 nm; UVA 320–400 nm) and visible (VIS 400–700 nm) absorption, photostability, phototoxicity in 3T3 mouse fibroblast culture vs. full-thickness reconstructed human skin (RHS), and its ability to inhibit reactive oxygen species formation that is induced by UVA on HaCaT keratinocytes. Later, we evaluated the antioxidant properties of the sunscreen formulation plus 0.5% fucoxanthin onto RHS to confirm its bioavailability and antioxidant potential through the skin layers. The compound was isolated from the alga Desmarestia anceps. Fucoxanthin, despite presenting chemical photo-instability (dose 6 J/cm2: 35% UVA and 21% VIS absorbance reduction), showed acceptable photodegradation (dose 27.5 J/cm2: 5.8% UVB and 12.5% UVA absorbance reduction) when it was added to a sunscreen at 0.5% (w/v). In addition, it increased by 72% of the total sunscreen UV absorption spectra, presenting UV-booster properties. Fucoxanthin presented phototoxic potential in 3T3 fibroblasts (mean photo effect 0.917), but it was non-phototoxic in the RHS model due to barrier function that was provided by the stratum corneum. In addition, it showed a significant inhibition of ROS formation at 0.01% (p < 0.001), in HaCat, and in a sunscreen at 0.5% (w/v) (p < 0.001), in RHS. In conclusion, in vitro results showed fucoxanthin protective potential to the skin that might contribute to improving the photoprotective potential of sunscreens in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

Fucoxanthin for Topical Administration, a Phototoxic vs. Photoprotective Potential in a Tiered Strategy Assessed by In Vitro Methods

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Concerning algal lipids, fucoxanthin 22 ( Figure 5), a xanthophyll-like carotenoid, is one of the most studied metabolites because of its beneficial health effects [18,103,132]. Indeed, there are many published reviews and research articles demonstrating and extolling, among others, the nutraceutical, antioxidant, anticancer, anti-obesity, antidiabetic, antimicrobial, and cardiovascular protective effects of fucoxanthin 22 [103,[132][133][134][135][136][137][138][139]. It is intended here to review the most relevant in vivo studies with pure fucoxanthin, highlighting the impact that each one had on the process of development of fucoxanthin as a drug with many potential therapeutic uses.…”

Section: Fucoxanthinmentioning

confidence: 99%

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

et al. 2019

View full text Add to dashboard Cite

Macroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes.Studies focusing on the preparation of macroalgae extracts and their chemical characterization revealed a large range of seaweed compounds with very interesting biological activities including antitumor, anti-inflammatory, antimicrobial, antidiabetic, antivirus, antihypertensive, fat-lowering, and neuroprotective activities [12][13][14][15].The large volume of studies proving the seaweed compound activities in in vitro systems [16][17][18][19] hints the need for further advancements in the knowledge about macroalgae compound efficiency in living systems (in vivo) and their use in the development of pharmaceuticals. In vitro studies are very relevant and yield very important information, but they only represent the first step of a long process, and the results obtained rarely reveal anything about the effects of a compound in vivo, because the responses observed in vitro can be magnified, diminished, or totally different in a more complex and integrated system. In fact, in vivo studies and clinical trials are those which contribute most to truly understanding the real potential of compounds as future pharmaceuticals.In this regard, the present work intends to present insight into the results obtained in the last few years regarding secondary metabolites, such as phlorotannins, halogenated compounds, fucoxanthin, and fucosterol isolated from macroalgae, involved in in vivo studies and clinical trials, identifying the research opportunities and knowledge gaps, to valorize these compounds and their natural resources. The intention is not to present an exhaustive survey of all published works, but rather a selection of authors based on the following criteria: in-depth studies involving pure compounds most characteristic f...

show abstract

“…In fact, cooked wakame has a higher FXN concentration than fresh samples [106], due to improved bioavailability upon cooking [37]. With regard to toxicity, most seaweeds are edible, and thus FXN isolated from seaweeds could be considered as a safe pharmaceutical ingredient [107]. Furthermore, a clinical trial reported no abnormalities or adverse effects exhibited by individuals who ingested FXN [95].…”

Section: Therapeutic Potential Of Fucoxanthin In Obesitymentioning

confidence: 99%

“…ASX showed health-promoting potential, such as considerable preventive and curative abilities against oxidative stress-related diseases including obesity [107]. It was suggested that ASX prevented HFD-induced obesity by lowering plasma triglycerides, total cholesterol levels, body weight, and adipose tissue size.…”

Section: Astaxanthin and Obesitymentioning

confidence: 99%

Therapeutic Effect of Seaweed Derived Xanthophyl Carotenoid on Obesity Management; Overview of the Last Decade

Ojulari

Lee

Nam

2020

IJMS

View full text Add to dashboard Cite

Present-day lifestyles associated with high calorie-fat intake and accumulation, as well as energy imbalance, have led to the development of obesity and its comorbidities, which have emerged as some of the major health issues globally. To combat the disease, many studies have reported the anti-obesity effects of natural compounds in foods, with some advantages over chemical treatments. Carotenoids, such as xanthophyll derived from seaweeds, have attracted the attention of researchers due to their notable biological activities, which are associated mainly with their antioxidant properties. Their involvement in oxidative stress modulation, the regulation of major transcription factors and enzymes, and their antagonistic effects on various obesity parameters have been examined in both in vitro and in vivo studies. The present review is a collation of published research over the last decade on the antioxidant properties of seaweed xanthophyll carotenoids, with a focus on fucoxanthin and astaxanthin and their mechanisms of action in obesity prevention and treatment.

show abstract

Fucoxanthin: A Promising Medicinal and Nutritional Ingredient

Cited by 163 publications

References 69 publications

Fucoxanthin for Topical Administration, a Phototoxic vs. Photoprotective Potential in a Tiered Strategy Assessed by In Vitro Methods

Fucoxanthin for Topical Administration, a Phototoxic vs. Photoprotective Potential in a Tiered Strategy Assessed by In Vitro Methods

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

Therapeutic Effect of Seaweed Derived Xanthophyl Carotenoid on Obesity Management; Overview of the Last Decade

Contact Info

Product

Resources

About